Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).

Autor: Aguado de la Rosa C; Department of Medical Oncology, Hospital Clínico San Carlos, Madrid, Spain., Cruz Castellanos P; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain., Lázaro-Quintela M; Department of Medical Oncology, Hospital Alvaro Cunqueiro, Vigo, Spain., Dómine M; Department of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain., Vázquez Estévez S; Department of Medical Oncology, Hospital Universitario Lucus Augusti, Lugo, Spain., López-Vivanco G; Department of Medical Oncology, Hospital Universitario de Cruces, Baracaldo, Spain., Fírvida Pérez JL; Department of Medical Oncology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Alonso Romero JL; Department of Medical Oncology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, IMIB-Arrixaca, Spain., Ferrera Delgado L; Department of Medical Oncology, Hospital Universitario de La Candelaria, Santa Cruz de Tenerife, Spain., García Girón C; Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain., Diz Taín P; Department of Medical Oncology, Hospital Universitario de León, León, Spain., Álvarez Álvarez R; Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain., Mut Sanchís P; Department of Medical Oncology, Hospital Son Llatzer, Palma de Mallorca, Spain., Fernández Cantón I; Department of Medical Oncology, Hospital Universitario de Jerez, Cádiz, Spain., Manrique Abós I; Department of Medical Oncology, Hospital San Pedro de Logroño, La Rioja, Spain., Martínez Aguillo M; Department of Medical Oncology, Hospital Universitario de Navarra, Pamplona, Spain., Gómez-Aldaraví Gutiérrez L; Department of Medical Oncology, Hospitalario Universitario de Albacete, Albacete, Spain., Ortega Granados AL; Department of Medical Oncology, Hospital Universitario de Jaén, Jaén, Spain., Álvarez Cabellos R; Department of Medical Oncology, Hospital Universitario de Toledo, Toledo, Spain., García Sebastián A; TFS Health Science at Pfizer, Madrid, Spain., García Sifuentes LF; Medical Department, Pfizer Oncology, Madrid, Spain., Reguart N; Department of Medical Oncology, Thoracic Oncology Unit, Hospital Clinic Barcelona, University of Barcelona, IDIBAPS, Barcelona, Spain. Electronic address: NREGUART@clinic.cat.

Publikováno v: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Nov; Vol. 173, pp. 83-93. Date of Electronic Publication: 2022 Sep 19.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.